Endocrinology Author Guidelines

• Articles funded by the National Institutes of Health (NIH), Wellcome Trust, Howard Hughes Medical Institute (HHMI), and Canadian Institutes of Health Research (CIHR) will be submitted to PubMed Central after final issue publication and will be made freely available in 12 months.
• There are additional US Government Agencies and private funders that have partnerships with the National Library of Medicine to leverage the PubMed Central infrastructure. A list of these organizations can be found at the PMC website. For specific information on how to comply with the policies of these funders, please see their websites. For information on depositing a paper in PubMed Central in compliance with a public access policy, see the PMC submission webpage.
• Please note that some funders (such as the Wellcome Trust and Research Councils UK) may require publication under an Open Access license and subsequent payment of a fee. Open access costs and publication charges are authorized grant expenses for which authors can seek reimbursement from the Wellcome Trust, Research Councils UK, or funders operating under their policies. These articles will contain the following language: "This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited."
• If your manuscript is accepted for publication, you will be asked at the proof stage to confirm the funding source of your paper and to agree to pay any applicable post-publication access fees.
• Reimbursement: The Endocrine Society will consider requests for reimbursement of APCs from funder and institutional customers in the event that we do not materially comply with their Open Access requirements. Contact [email protected].

• Read the Editorial Policies. Note: Endocrine Society journals allow submissions from preprints: see Preprint Repositories and Prior Publication.
• Format Neutral Submission: New manuscripts may be submitted format neutral, as a single Word, RTF, or PDF file with continuous line numbering. Technical formatting such as reference layout and order of components is not scrutinized for compliance at this initial stage. If the required information is present (complete title page, all author information, abstract, full text, line numbering, figures and tables, references, etc.) the manuscript will be assessed solely on its scientific merit. Note that metadata extraction will work only for manuscripts uploaded as Word files.
• Submit paper in English through the Editorial Manager system.
• Inclusive and Person-First Language: Please use inclusive and person-first language in manuscripts by describing people as having a condition or disease rather than the condition or disease being their identity. For example, use “people with obesity” or “person with diabetes” rather than “obese people” or “diabetic.”  We also recommend consulting the AMA Manual of Style on Terms for Persons With Diseases, Disorders, or Disabilities.
• Use a double-spaced, single-column format with 1-inch margins.
• Use continuous line numbering throughout the manuscript. Manuscripts submitted without line numbers will be returned.
• Paginate the entire document.
• Place all tables and figures after the references and clearly label each.
• Gather needed information prior to starting the submission process in Editorial Manager:
• Full names, institutions, and email addresses for each author.
• Submitting authors are required to provide an ORCiD when uploading a manuscript.
• Appropriate funding information for each author.
• Disclosure information for each author.
• Original manuscript number if manuscript being submitted was previously rejected by the journal to which it is being resubmitted.
• No cover letter is needed. A text block is provided during the submission process for special requests.
• Appropriate figure file specifications as detailed in the Figure Guidelines have been followed.

• At revision, two versions of your manuscript will be required: (1) A marked-up copy to be used for editor and reviewer purposes that indicates all changes made to the text, legends, and tables with either highlighting, colored text, or tracked changes and (2) A clean, un-marked copy that has all color and mark-up removed from text, legends, and tables that will be used by production, should your manuscript be accepted. Both versions of your manuscript should be prepared in and submitted as MS Word files.
• Please note that aside from one copy showing color or markup, the two copies of your manuscript should both include all revisions and be identical. The clean copy should contain all revisions reflected in the marked-up version, but have tracked changes accepted and highlighting/colored text reverted to black and white.
• Use continuous line numbering throughout both the marked manuscript and the clean manuscript document. Manuscripts submitted without line numbers will be returned.

Permission to Reproduce or Adapt Figures/Tables

Adapted and reproduced figures and tables are allowed only in mini-reviews. Note that the permissions staff will assist the author with identifying the appropriate type of permission to obtain. When determining the status of a figure / table, please use these definitions:

ORIGINAL: If you created a figure or table specifically for the work being submitted, this is an original and no permissions are required.

REPRODUCED: If a figure or table appears in a new publication exactly as it appeared in the original publication, then it is reproduced. Permission must be given by the publisher and attribution to the original source must be provided.

ADAPTED: If a figure or table is adapted, it is modified from its original appearance but still closely resembles the original. Permission must be given by the publisher and attribution to the original source must be provided.

If a figure or table uses elements from another source, or multiple sources, authors are responsible for determining if the figure is “Adapted” or “Transformative”.

ADAPTED:

If you create a figure or table that (1) includes someone else’s previously published data or illustrative elements AND (2) their data/illustrative elements are incorporated into your work to illustrate similar facts or conclusions, then your reproduction of their data/illustrative elements is a derivative work (or “adaptation”). Permission must be obtained from the owner and a citation to the original work must be provided in your figure/table legend.

TRANSFORMATIVE:

If your use of someone else’s previously published data or illustrative elements in your own figure or table goes beyond simply adapting their work as described above, then your use may be “transformative.” If you believe the work is transformative, you may not need to obtain permission, but you do need to provide a citation.

To be transformative, your use should add something uniquely new to the underlying data/illustrative elements or serve a different function, purpose, or character than the original work.  One factor to consider is whether the new work will be competitive with or as supplanting the demand for the original. Transformative works are not usually competitive with the original work. If you believe your use is transformative, you need to seek guidance from your appropriate institutional officers to determine the legal status of the figures and tables you include with your submitted manuscript and provide the appropriate language in the figure/table legend.

If you determine your work is “transformative” and does not require permission from the owner, you must certify it as such and include the source in the figure/table legend. For example: From Brown J Widgets Today, 2018; 100(6). It is important that specific cases be clearly assessed by the authors and if needed, the institution(s) responsible for the work submitted by the authors. Authors should be prepared to provide the editorial office with documentation showing the original figure or table and describing the transformative nature of the new work.

• Use the international system of units (SI) where possible, or other metric units. If non-metric units are mentioned, please give their SI equivalent in parentheses.
• Temperature should be expressed in degrees Celsius (e.g., 28°C) and time of day using the 24-hour clock (e.g., 0800 h, 1500 h).
• Molecular weight should not have units (daltons).
• All nonstandard abbreviations in the text must be defined immediately after the first use of the abbreviation.

• The 3 major classes of mammalian sex steroids — androgens, estrogens, and progestins (or progestagens or gestagens) — correspond to the well-defined androgen, estrogen, and progesterone receptors. The principal bioactive sex steroid and natural ligand for each class is testosterone, estradiol, and progesterone, respectively. Estrogen(s) and progestin(s) are classes of steroids. Synthetic steroids or extracts can be considered as members of a generic steroid class, but are distinct from the natural cognate ligand. Therefore, the terms androgens, estrogens, and progestins (or progestagens or gestagens) should be used when referring to the class of hormones, whereas when a specific natural or synthetic steroid is being used or assayed the particular compound must be specified.
• Apart from accepted trivial names, steroids should be named according to the systematic nomenclature of the IUPAC convention on Nomenclature of Steroids (Moss et al Pure & Applied Chemistry 61:1783–1822, 1989) at first mention in a single footnote defining all letter abbreviations. Subsequently, generic or trivial names or letter abbreviations, but not trade-names, should be used.
• The accepted trivial names include cholesterol, estrone, (17)estradiol, estriol, aldosterone, androsterone, etiocholanolone, dehydroepiandrosterone, (5) dihydrotestosterone, testosterone, androstenedione, pregnenolone, progesterone, corticosterone, deoxycorticosterone, cortisone, cortisol. Trivial names may be modified by prefixes indicating substituents (as in 17-hydroxyprogesterone for 17-hydroxy-4-pregnene-3,20-dione), double bonds (as in 7-dehydrocholesterol for 5,7-cholestadien-3-ol) and epimeric configurations of functional groups provided the locus of epimerization is indicated (as in 3-epiandrosterone for 3-hydroxy-5-androstan-17-one).
•  Nomenclature of Vitamin D Metabolites: Analogous and Structurally Related Compounds

___ The title must be 120 characters and spaces or fewer and provide a concise and informative statement of the article’s contents. Avoid titles presented as questions and wordplay or comical titles, as these will usually not be understood globally.  

___ Authors’ full names and institutions.

___ No more than six keywords.

___ Corresponding author’s contact information.

___ Name and address of author to whom reprint requests should be addressed.

___ Any grants or fellowships supporting the writing of the paper.

___ Disclosure summary.

___ Does not refer directly to the text or references.

___ Describes in complete sentences the purpose, methods, results, and main conclusions.

___ Aimed to a general audience with specialized terminology kept to a minimum.

___ An introductory statement that places the work in historical perspective, explaining its intent and significance.

___ Describes in sufficient detail for other investigators to repeat the work.

___ Make all appropriate resource deposits. See Resource Deposits for full instructions.

___ Results should briefly present the experimental data in text, tables, or figures.

___ Focus Discussion on the interpretation and significance of the findings or information reviewed with concise objective comments that describe their relation to other work in that area.

___ Include names of people who contributed to the study but did not meet the requirements for authorship.

___ Options described in the Data Availability section.

___ Use the AMA (American Medical Association) Style Guide for allowable references. List all authors for the initial submission. See examples of correctly formatted references below.

___ List references in consecutive numerical order (in parentheses) in the text, figures, and tables and list in the same numerical order at the end of the manuscript. References in tables and figures should be cited in sequence with those in the text. The numbering should shift to the table or figure after the table or figure is first mentioned in the text. All references in the table or figure should be cited in sequence. The numbering of citations should then return to the text and continue for subsequent citations. NOTE: Provided sequence is preserved, it is acceptable for a reference to appear only in a figure or table. EXAMPLE: If Table 1 contains five references and the first citation of the table occurs immediately after Ref. 10 in the text, then the references numbered within the Table 1 must be Refs. 11-15. Within the text, after the first citation for Table 1, reference sequencing resumes with Ref. 16, and so on.

___ Supplemental data must be submitted to a repository and cited in the manuscript bibliography. For more information see Extended Data Sets and Supplemental Materials.

___ Do not cite the following in the reference list:

___ “In press” manuscripts can be included in the reference list if they meet the following criteria:

___ Abstracts: If it is necessary to cite an abstract because it contains data not published elsewhere, it must be designated as such in the text and in the reference list.

___ Examples of references:

___ Provide all legends separately after the references.

___ Mini-reviews only: if figure or table is reproduced or adapted from a previously published source, include an acknowledgment line at the end of the legend.

___ Clearly and completely describe the content of the figure or table so it can be understood without reference to the text.

___ Explain any symbols or the significance of any color that is important for understanding the content.

___ Use color descriptors as necessary.

___ Figures and tables must be numbered to appear sequentially. Figure 1 must be followed by Figure 2 and any subsequent figures in numerical order, and Table 1 must be followed by Table 2 and any subsequent tables in numerical order.

___ Construct tables simply and design them to be clear without reference to the text.

___ Provide a concise heading and footnotes if needed.

___ Generally, submitted tables should not consist of more than four or eight manuscript pages (for portrait or landscape presentation, respectively). This is so that the composed, typeset tables are limited to two journal pages (if in standard, portrait orientation) or four journal pages (if in landscape orientation) with normal font size. If, when composed, tables exceed the specified limits, production and ultimate publication will be delayed until the requirements are met.

___Tables should be created using the Insert Table feature in Microsoft Word and uploaded as separate files in .doc or .docx format or placed at the end of the manuscript document. 

___ Tables cannot include color or graphics. 

___ The Endocrine Society uses an image forensic screening process to determine if manipulation has occurred.

___ No specific feature within an image may be enhanced, obscured, moved, removed, or introduced.

___ The grouping of images from different parts of the same gel, field or exposure, or from different sources, must be made explicit by the arrangement of the figure (e.g., dividing lines) and in the text of the figure legend.

___ The author agrees to provide the editorial office with the original data used to produce the figure if requested.

___ Review the detailed Digital Art Guidelines. 

___ If using color, present information so as to minimize difficulty for readers with color vision deficiency, e.g., by using symbols and an optimized color palette. Please consult Figure Preparation Guidelines for Color Vision Deficiency.

___ Titles should be clear and informative. Use minimal wording on figures and confine explanation of figures to their legends.

___ Legends should clearly and completely describe the appropriate content.

___ Figures must be numbered to appear sequentially. Figure 1 must be followed by Figure 2 and any subsequent figures in numerical order.

___ Figure Preparation:

___ Graphs:

___ Supplemental data are no longer allowed as uploads submitted with a manuscript. Supplemental data must instead be submitted to a repository and the accession number provided in the Reference Section and cited in the manuscript. For more information see Extended Data Sets and Supplemental Materials.

• Authors must affirm that the Work submitted for publication is original and has not been published other than as an abstract or preprint in any language or format and has not been submitted elsewhere for print or electronic publication consideration. Authors must also affirm that each person listed as authors participated in the Work in a substantive manner, in accordance with ICMJE authorship guidelines, regardless of any use of AI or machine-learning tools in its preparation, and is prepared to take public responsibility for it. All authors consent to the investigation of any improprieties that may be alleged regarding the Work. Each author further releases and holds harmless the Endocrine Society from any claim or liability that may arise therefrom.
• Persons who contributed to the study (e.g., provision of materials or reviewing the manuscript) but do not meet the requirements for authorship, or who die before otherwise meeting the International Committee of Medical Journal Editors (ICMJE) criteria for full authorship, may be listed in the Acknowledgments. The corresponding author is responsible for informing each person listed in the acknowledgment section that they have been included and providing them with a description of their contribution so they know the activity for which they are considered responsible. Each person listed in the acknowledgments must give permission for the use of his or her name. It is the responsibility of the corresponding author to collect and maintain this information.
• Medical writers should be listed in the Acknowledgments section and not included in the authorship line.
• During the peer-review process, the author designated to upload the manuscript to Editorial Manager responds for all authors when completing the online submission form. At the time of submission, all co-authors will receive authorship verification emails to which they must respond. This confirmation must be received before the decision on a first revision can be sent. It is imperative that all co-authors are listed on the submission form and that the email address of each is correct.
• Submitting Author, First Author, and Corresponding Author.
  • The Submitting Author is the single member of the authorship group who uploads the manuscript files to Editorial Manager and is the main recipient of communication during peer review and production. Submitting authors are required to use an ORCiD when uploading a manuscript. Go to the orcid.org to register for an ORCiD identifier.
  • The First Author is the first named author in the authorship list. Only one additional co-first author is allowed. The names should be indicated with an asterisk (*) on the title page of the manuscript text. A footnote should be included indicating that this is a shared role.
  • The Corresponding Author should be designated on the title page of the manuscript text and in a footnote. Include an ORCiD for the Corresponding Author on the title page. A maximum of three co-corresponding authors is allowed.​ Each must have an ORCiD. 
  • If no member of the authorship group uses an institutionally-provided email address that reflects their current affiliation, then the Submitting Author must upload a signed letter from a supervisor/ line manager within their institution who does have an institutionally-provided email address to confirm that the manuscript represents work by the submitting author and their coauthors. The editorial staff will contact the person indicated in the letter and the manuscript will be on hold until positive confirmation of the submitting author’s institutional affiliation is received from the supervisor / line manager.

• Authors must present a clear, accurate, and complete account of the research performed.
• Each manuscript should describe a complete study or a completed phase of an extended study.
• For Research Articles, the Submitting Author must upload the institutional ethical approvals (e.g. IRB, animal care committee, etc.) for the work (with English translations if the original documents are not in English). If no ethical approval was needed, a waiver document or an authors’ justification that describes why no institutional ethical approval was needed may be uploaded. These documents will be seen by the Editors and reviewers but will not be published with the manuscript.
• When some of the results are to appear in another journal, in publications of congresses, symposia, workshops, etc., details plus a copy of the other paper(s) should be supplied to the editor.
• Any preliminary accounts or abstracts of the work that are already published must be referenced in the complete report.
• The use of artificial intelligence (AI) tools must be disclosed during the submission process and also described in the Methods or Acknowledgments sections of the text.

• Describe the work in sufficient detail to allow others to repeat the work
• Adhere to the journals’ policy regarding preparation of digital images
• Include all relevant data, including those which may not support the hypothesis being tested
• Cite those publications which have a direct bearing on the novelty and interpretation of the results, including original findings and seminal works
• Establish the integrity of third party resources, such as data repositories located on external websites and servers, used and cited in the work
• Deposit large datasets from gene expression microarrays, SNP arrays, and high-throughput sequencing studies in a public repository. Accession numbers must appear in the Reference section of the manuscript and be cited in the text of the manuscript. Deposition of other large datasets in a public repository is strongly encouraged. Other supporting datasets must be made available to any interested researcher from the date of first publication from the authors directly.
• Make unique resources (including but not limited to cell lines, software programs, organisms, antibodies, etc.) available to other investigators for academic research purposes
• If there are restrictions to the availability of such resources, authors must disclose this to the editors at the time of submission, and include a comment on the restrictions in the Materials and Methods section. The Editors may deny further publication rights in the journal to authors unwilling to abide by these principles.
• Provide antibody RRIDs (Research Resource Identifiers) for antibodies and ELISAs, including commercial ELISA kits, used in the research. Provision of RRIDs for other unique research resources is recommended.
• Ensure no substitution, addition, or deletion of data or text during the proof correction process (after acceptance). Answers to author queries and changes to typographical or printer’s errors may be made to proofs. Any other changes will require that the proofs be returned to the editorial office for re-review of the manuscript.
• After manuscript submission, no authorship changes (including the authorship list, author order, or author role) should be made unless there is a substantive reason to do so. The Executive Editor and all co-authors must agree on the change(s), and neither the Journal nor the publisher mediates authorship disputes. If there are any changes to the authorship line from the originally submitted manuscript, the corresponding author must send to the Editorial Office a brief letter, signed by all authors, stating that they agree to change. The manuscript will be held from that point until a decision is made by the Executive Editor whether to allow the change.
• If individuals cannot agree on the authorship of a submitted manuscript, peer review will be put on hold until the dispute is resolved among the individuals and their institution(s). If there is no resolution to the authorship dispute two months after the editorial office learns of the dispute, the manuscript will be withdrawn from consideration by the journal. If an authorship dispute or change arises after a paper is accepted, contact OUP’s Author Support team. COPE provides guidance for authors on resolving authorship disputes. 
• For industry-sponsored studies, the author affirms that all co-authors have had full access to primary study data and the ability to perform all relevant analyses.

Institutional / Employer-Affiliated Email Address Requirement for Authors

Owing to changes in the publishing environment that have increased the need for publishers to be vigilant about authors’ identities, Endocrine Society journals will require, starting on February 24, 2025, that all authors submitting manuscripts to the journals use an institutional or employer-assigned email address.

This requirement ensures greater accountability for scientific quality and authenticity by linking articles to the institutions that provided the resources to perform the reported research. Personally obtained commercial email addresses cannot provide a verifiable connection between the declared name of an author and the recipient. In addition, personal commercial email addresses make it possible for a researcher’s name to be used fraudulently.

The following guidelines will apply to all manuscript submissions, starting February 24, 2025:

• All authors must use a recognized institutional or employer-assigned email address. A personal (commercial) email address can be used during the submission process in addition to the institutional or employer-assigned email address but not in place of it.
• If an author does not have an institutional or employer-assigned email address, the following procedures apply:
  • Manuscripts with 5 or fewer authors can have only 1 co-author who does not have an institutional or employer-assigned email address, and the AFFIRMATION PROCESS described below must be followed.
  • Manuscripts with more than 5 authors can have only 2 co-authors who do not have institutional or employer-assigned email addresses, and the AFFIRMATION PROCESS described below must be followed.
  • If a manuscript has a single author and that person does not have an institutional or employer-assigned email address, they should contact [email protected] to determine the best way to confirm identity.
  • AFFIRMATION PROCESS: The submitting author, who must have an institutional email address, will provide the editorial office with a written statement, signed by all authors, attesting that the commercial email address used by the co-author without an institutional or employer-assigned email address is the person they present themselves to be and that they meet the journal’s authorship criteria.
• Any authors added after initial submission must have an institutional or employer-assigned email address.

• All studies involving human subjects or human tissue must be in accordance with the principles set out in the Declaration of Helsinki and must have been formally approved by the appropriate institutional review board, ethical review committee, or equivalent.
• The study populations — details of age, race, and sex as relevant to the material — must be described in detail. 
• In all experiments involving human subjects, it should be documented that informed consent was obtained from the participants and that an institutional human research committee had approved the investigations. This should be clearly stated in the Methods section of the manuscript.
• In text, tables and figures subjects must be identified by number or letter rather than by initials or names. Photographs of patients’ faces should be included only if scientifically relevant. Authors should obtain written consent from the patient for use of such photographs and the manuscript should state that this has been obtained.
• For further details, see the Ethical Guidelines.

• A statement confirming that all animal experimentation described in the submitted manuscript was conducted in accord with accepted standards of humane animal care, as outlined in the Ethical Guidelines, should be included in the manuscript. Numbers of animals used in each group and in each experiment should be included.
• All research animals must be acquired and used in compliance with federal, state, and local laws and institutional regulations. In particular, the Society recommends that animals be maintained in accordance with the Guide for the Care and Use of Laboratory Animals [1996 (7th ed.) Washington, DC: National Research Council, National Academies Press]
• Research animals must receive appropriate tranquilizers, analgesics, anesthetics and care to minimize pain and discomfort during preoperative, operative, and postoperative procedures. The choice and use of drugs must be made in accordance with the NRC Guide. Where the use of anesthetics would negate the results of the experiment, the protocol must be clearly justified and approved by the Committee on Animal Care and Use of the local institution and according to accepted veterinary medical practice.
• The health of the animals must be properly monitored. If either the study or the condition of the animals requires that they be killed, it shall be done in a humane manner.
• The manuscript must indicate that the studies were approved by the authors’ institutional committee on animal care.

 Reviewers are required to provide a confidential, expert, critical, and constructive appraisal of research reports in their fields of knowledge and experience in a fair and unbiased manner.

 Reviewers should complete their assignments within the editor’s deadline. Should a delay occur, the reviewer has the obligation to notify the editor immediately.

 Reviewers should not review a manuscript if:

 Employment at the same institution as one of the authors does not automatically represent a conflict. Having previously reviewed the article for another journal does not disqualify a reviewer, although the editor should be informed so the reviewer’s perspective can be considered.

 Reviewers who need to recuse themselves should notify the editor promptly, preferably with an explanation. If reviewers are uncertain whether they should recuse themselves, they should consult with the editor.

 The reviewer should strive to provide accurate and detailed criticisms, and the review should be supported by appropriate references, especially if unfavorable. The reviewer should also note whether the work of others is properly cited. If the reviewer notes any substantial resemblance of the manuscript being reviewed to a published paper or to a manuscript submitted at the same time to another journal, they should promptly report this to the editor.

 The reviewer should aim to help the author improve future work. For example, if the author uses outdated or inexact terminology, provide guidance on best practices.

 No part of the manuscript under review should be revealed to another individual without the permission of the editor. If a reviewer consults a colleague on a particular point, the name of the collaborator or consultant should be reported to the editor. A reviewer must obtain through the editor written permission from the authors to use or disclose any of the unpublished content of a manuscript under review.

 Reviewers must not use artificial intelligence (AI) tools when evaluating a manuscript due to the loss of confidentiality that occurs when sharing information about the content of the manuscript with Large Language Models (LLMs) and AI tools. These tools compromise the confidential nature of peer-review and they cannot provide a substitute for the expert opinion and judgement that we seek from reviewers.

• All work must be free of falsification, fabrication, and plagiarism, as defined by the US Department of Health and Human Services Office of Research Integrity. Please follow this link for further information.
• Manuscripts submitted to this Endocrine Society journal are screened for plagiarized content against the iThenticate database.
• The editors reserve the right to reject manuscripts describing research that does not meet acceptable standards of research behavior as determined by the Belmont Report, the Geneva Convention, the Declaration of Helsinki, and the Endocrine Society Code of Ethics.
• Scientific misconduct and unethical acts include, but are not limited to, plagiarism, fabrication, falsification, redundant or duplicate publication, violation of federal, state or institutional rules, and honorary authorship. The Endocrine Society’s journals follow the guidelines promulgated by the Committee on Publication Ethics for ensuring the integrity of published articles.
• In the event that an Endocrine Society journal receives allegations of misconduct relating to an article that was published or is being considered for publication, the Editor-in-Chief will follow procedures recommended by the Committee on Publication Ethics (COPE).

• An Associate Editor will determine if a submitted manuscript should be Rejected Without Review or sent for single-anonymized peer review.
• If the manuscript is Rejected Without Review, the author is notified immediately.
• If the manuscript is sent for peer review, the Associate Editor will select two reviewers who are asked to disclose any potential conflicts of interest.
• The Associate Editor makes a decision on the disposition of the manuscript. Decisions can be Accept, Reject, or Revision Needed.

• If the author decides to resubmit a rejected manuscript within one year of the initial rejection, the Editor-in-Chief must give permission. After one year, it can be resubmitted as a new manuscript, although the author should reference the original manuscript at resubmission.
• If the article is declined by the journal, the author may be offered the opportunity to transfer the manuscript to Journal of the Endocrine Society for peer review. If a manuscript undergoes peer review before rejection, the reviewers will be given the opportunity to transfer their comments with the manuscript. 

• If the manuscript is sent back to the author for revision, the author will have two months to prepare a revision. Extension requests must be directed to the Editor-in-Chief and sent to [email protected].
• When the revision is submitted, it is sent back to reviewers if the Associate Editor determines that this is needed. If not, a final decision of Accept or Reject will be made.

• The manuscript will be sent to production following completion of permissions review (if the article includes art that is reproduced or adapted from a previous publication), and the authors’ provision of any necessary permissions to the journal. Within seven working days of the article’s being submitted to production, an Advance Article version (non-copyedited) will be posted on the journal site for citation and listing by PubMed. No changes can be made to the Advance Article version.

• Accepted articles will not be held from publication at the request of the authors unless they have contacted the Chief Publications Officer at [email protected] at some point during the review process, at least 1 week prior to acceptance, and received permission for the hold from the CPO and any co-authors.

• A copyedited proof will be sent to the author within three weeks. Authors should review the proof and return requested corrections within 24 hours. The final version of the article cannot be published until authors return the proofs. The publisher will formally withdraw the article if the authors have not responded with final approval within three months after the article acceptance date.

• Once corrections are returned and queries are addressed and resolved, the final version of the article will be posted on the journal site and will replace the Advance Article listing in PubMed. If the article is eligible for PubMed Central inclusion, it will be deposited at this time.
• Tips for promoting accepted and published articles are detailed in the Author Resource Center.

• The sex of research subjects must be indicated.
• If both males and females were included in the study, the numbers of subjects from each sex should be indicated, and it must be indicated whether sex was considered a factor in the statistical analysis of the data.
• Likewise, the sex from which human primary cell cultures or human tissues were obtained must be indicated.
• The authors are also encouraged to include the sex of human cell lines.

• Where applicable, the strain and sex of animals used in research studies must be indicated.
• If both males and females were used, the numbers of animals from each sex should be indicated, and it must be indicated whether sex was considered a factor in the statistical analysis of the data.
• Likewise, the sex from which primary cell cultures or tissues were obtained should be indicated.
• The authors are also encouraged to include the sex of cell lines.

• Use standard terminology for variants, providing rs numbers for all variants reported. Where rs numbers are provided, the details of the assay (primer sequences, PCR conditions, etc.) should be described very concisely. Describe measures taken to ensure genotyping accuracy, e.g., percentage of genotype calls, number of duplicate samples that were genotyped, and percentage concordance.
• Provide approved GDB/HUGO approved gene names, in the appropriate cases and italics.
• Provide linkage disequilibrium (LD) relationships between typed variants.
• Provide information and a discussion of departures from Hardy-Weinberg equilibrium (HWE). The calculation of HWE may help uncover genotyping errors and impact on downstream analytical methods that assume HWE.
• Provide raw genotype frequencies in addition to allele frequencies. It is also desirable to provide haplotype frequencies.
• Provide the criteria they have used to select tagSNPs.
• Denote the boundaries considered when studying SNPs within a gene of interest. Primer sequences, the conditions for PCR, and the depth of sequencing should be provided either in the manuscript or in a public data repository.

Assay validation: Bioassay and immunoassay (including radioimmunoassay, enzyme immunoassay, and immunometric assay) performance estimates should be accompanied by an appropriate measure of the precision of these estimates.

For both bioassays and immunoassays (whether laboratory-developed or commercially obtained), include data relating to within-assay and between-assay variability. If all relevant comparisons are made within the same assay, the latter may be omitted.

Authors should be aware that the precision of a measurement depends upon its position on the dose-response curve.

In presenting results for new assays, it is necessary to include data on the following:

Pulse analysis: Data from studies of pulsatile hormone secretion should be analyzed using a validated, objective pulse detection algorithm. The algorithm used should require that false-positive rates of pulse detection be defined in relation to the measurement error of the data set being analyzed, and the methods used to determine the measurement error should be described or cited. The author(s) also should describe the methods used.

Data Analysis: It is the author’s responsibility to document that the results are reproducible, using appropriate statistical tests. Data pre-processing steps should be described, and removal or modification of data values must be justified. Full details of statistical tests (including post-hoc tests, if performed) should be provided. Effect sizes and confidence intervals should be reported, and the number of sampled units upon which each reported statistic was based should be stated. Provide exact P values, not a range. Avoid relying only on a P value to evaluate a result. For representative results, report the number of times the measurements were repeated. Authors should use appropriate nonparametric analysis when the data do not meet the assumptions of parametric statistics.

When data points are fitted with lines (as in Scatchard or Lineweaver-Burk plots), the method used for fitting should be specified.

• Non-clinical studies (in vitro or animal experiments): Where experiments include a contemporaneous randomly assigned, matching control group, assay measurements must be sufficiently accurate to justify valid comparison between groups within that experimental setting. For commercial sex steroid assays typically validated for human serum in multiplex platform or kit formats used in non-clinical studies, any change in species and/or matrix must be validated by the assay laboratory to verify acceptable quantitative accuracy, precision and specificity for each analyte.
• Clinical studies: Because data from clinical research are likely to be extrapolated quantitatively to populations beyond those in the study, sufficiently stringent assay validation is required to ensure reliable comparison of measurements between different populations and laboratories. Quantitative assay results must be verifiably traceable to a common reference standard (certified reference materials) where available. Information about available reference standards can be obtained from CDC’s Clinical Standardization Programs ([email protected], https://www.cdc.gov/clinical-standardization-programs/php/hormones/index.html).

 Examples of issues with assays that could preclude valid results include:

Calibration for clinical studies:

 Accuracy for all studies:

 Sensitivity for all studies:

 Precision for all studies:

 Stability and pre-analytical processing effects on measurement for all studies:

 Specificity for all studies:

1.  Clinical Chemistry
2.  FDA
3.  EMEA

• when a cell line is received from an outside source (repository, other investigator)
• for new established cultures
• if many different cell lines are employed within a given laboratory

The Endocrine Society requires that authors provide a statement about the availability of data generated or analyzed in the submitted manuscript. This statement will be included in the final version of accepted manuscripts. During the submission process, authors are asked to select a statement that best describes their data availability and to include the selected statement in the manuscript document, just before the reference list. This section of the manuscript should be labelled “Data Availability.” Options for these statements are below:

• Original data generated and analyzed during this study are included in this published article or in the data repositories listed in References.
• Some or all datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.
• Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
• Restrictions apply to the availability of some or all data generated or analyzed during this study to preserve patient confidentiality or because they were used under license. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided. [Please note that selecting this option does not avoid the requirement to deposit ‘omics and other large datasets in a suitable repository.]

If you find that the list of statements does not reflect your situation, please select the one that is closest to facilitate submission of the manuscript and then contact Tim Beardsley, Executive Editor, at [email protected].

New Amino Acid or Nucleotide Sequences and New/Novel Compounds